Références
Cosne J, Bourrier A, Laharie D, Bouhnik Y, Nahon S, Bonnet J, et al. Accelerated step-care therapy with early azathioprine vs conventional step-care therapy in Crohn’s disease. a randomized study. Endoscopy 2012;44(Suppl 1):A2.
Colombel JF. Vedolizumab induction therapy for Crohn’s disease: results of Gemini II, a randomized, placebo- controlled, doubleblind, multicenter phase 3 trial. Endoscopy 2012;44(Suppl 1): A32.
Colombel JF. Vedolizumab maintenance therapy for Crohn’s disease: results of Gemini II, a randomized, placebo- controlled, double-blind, multicenter phase 3 trial. Endoscopy 2012;44(Suppl 1):A32.
Rutggeerts P, Feagan G, Marano C, Strauss R, Johanns J, Zhang H, et al. A phase 2/3 randomized, placebo-controlled, doubleblind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: pursuit sc. Endoscopy 2012;44(Suppl 1):A78.
Rutggeerts P, Feagan G, Marano C, Strauss R, Johanns J, Zhang H, et al. A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab maintenance therapy in patients with moderately to severely active ulcerative colitis: pursuit maintenance. Endoscopy 2012;44(Suppl 1):A79.
Colombel JF, Thakkar RB, Castillo MM, Robinson AM, Yang M, Skup M, et al. Risk of malignancy, infection, serious infection, and acute health care use in patients with Crohn’s disease treated with adalimumab vs. Immunosuppressants. Endoscopy 2012;44(Suppl 1):A23.
Colombel JF, Thakkar RB, Robinson AM, Skup M, Yang M, Swallow E, et al. Comparative colorectal cancer risk in patients with ulcerative colitis treated with adalimumab versus conventional therapy. Endoscopy 2012;44(Suppl 1):A285.
Rahier JF, Moreels T, Peeters H, D’Haens G, Franchimont D, de Vos M, et al. Impact of immunosuppressant and anti-TNF treatment on common infections in IBD patients. Endoscopy 2012;44(Suppl 1):A46.
Kestens C, van Oijen M, Mulder C, Ponsioen C, van Bodegraven A, Dijkstra G, et al. A multicenter retrospective head-to-head comparison of adalimumab and infliximab for Crohn’s disease. Endoscopy 2012;44(Suppl 1):A80.
Bessissow T, Lemmens B, Ferrante M, Bisschops R, Van Steen K, Geboes K, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Endoscopy 2012;44(Suppl 1):A12.
Bessissow T, Bisschops R, Ferrante M, Baert F, Ballet V, Willekens H, et al. 5-aminosalicylate is not protective from dysplasia in ulcerative colitis patients with mucosal healing: a nested case-control study. Endoscopy 2012;44(Suppl 1):A24.
Bisschops R, Bessissow T, Baert F, Ferrante M, Ballet V, Willekens H, et al. Chromo-endoscopy versus narrow band imaging in ulcerative colitis: a prospective randomized controlled trial. Endoscopy 2012;44(Suppl 1):A26.
Neumann H, Vieth M, Grauer M, Günther C, Atreyal R, Neurath MF. Virtual chromoendoscopy with i-scan for prediction of severity and disease extent in patients with inflammatory bowel disease — a randomized double-blind controlled study. Endoscopy 2012;44(Suppl 1):A161.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Bulois, P., Bernardini, D. Compte-rendu de congrès UEGW 2012, Amsterdam, 20 au 24 octobre 2012 : les MICI. Acta Endosc 42, 317–319 (2012). https://doi.org/10.1007/s10190-012-0286-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10190-012-0286-9